HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chitambar, C. R. Articles by Wereley, J. P. Search for Related Content PubMed PubMed Citation Articles by Chitambar, C. R. Articles by Wereley, J. P. Social Bookmarking                      What's this?

Volume 272, Number 18, Issue of May 2, 1997 pp. 12151-12157
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Resistance to the Antitumor Agent Gallium Nitrate in Human Leukemic Cells Is Associated with Decreased Gallium/Iron Uptake, Increased Activity of Iron Regulatory Protein-1, and Decreased Ferritin Production

(Received for publication, October 23, 1996, and in revised form, January 17, 1997)

From the Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226

The mechanism of drug resistance to gallium nitrate is not known. Since gallium can be incorporated into ferritin, an iron storage protein that protects cells from iron toxicity, we investigated whether ferritin expression was altered in gallium-resistant (R) CCRF-CEM cells. We found that the ferritin content of R cells was decreased, while heavy chain ferritin mRNA levels and iron regulatory protein-1 (IRP-1) RNA binding activity were increased. IRP-1 protein levels were similar in gallium-sensitive (S) and R cells, indicating that R cells contain a greater proportion of IRP-1 in a high affinity mRNA binding state. ⁵⁹Fe uptake and transferrin receptor expression were decreased in R cells. In both S and R cells, gallium inhibited cellular ⁵⁹Fe uptake, increased ferritin mRNA and protein, and decreased IRP-1 binding activity. Gallium uptake by R cells was markedly diminished; however, the sensitivity of R cells to gallium could be restored by increasing their uptake of gallium with excess transferrin. Our results suggest that R cells have developed resistance to gallium by down-regulating their uptake of gallium. In parallel, iron uptake by R cells is also decreased, leading to changes in iron homeostasis. Furthermore, since gallium has divergent effects on iron uptake and ferritin synthesis, its action may also include a direct effect on ferritin mRNA induction and IRP-1 activity.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. R. Chitambar, D. P. Purpi, J. Woodliff, M. Yang, and J. P. Wereley Development of Gallium Compounds for Treatment of Lymphoma: Gallium Maltolate, a Novel Hydroxypyrone Gallium Compound, Induces Apoptosis and Circumvents Lymphoma Cell Resistance to Gallium Nitrate J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1228 - 1236. [Abstract] [Full Text] [PDF]

				M. Yang, S. H. Kroft, and C. R. Chitambar Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate Mol. Cancer Ther., February 1, 2007; 6(2): 633 - 643. [Abstract] [Full Text] [PDF]

				N. P. Davies, Y. S. Rahmanto, C. R. Chitambar, and D. R. Richardson Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 153 - 162. [Abstract] [Full Text] [PDF]

				P. Heffeter, M. Pongratz, E. Steiner, P. Chiba, M. A. Jakupec, L. Elbling, B. Marian, W. Korner, F. Sevelda, M. Micksche, et al. Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A) J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 281 - 289. [Abstract] [Full Text] [PDF]

				J.-Y. Li, G. Ram, K. Gast, X. Chen, K. Barasch, K. Mori, K. Schmidt-Ott, J. Wang, H.-C. Kuo, C. Savage-Dunn, et al. Detection of intracellular iron by its regulatory effect Am J Physiol Cell Physiol, December 1, 2004; 287(6): C1547 - C1559. [Abstract] [Full Text] [PDF]

				C. R. Chitambar and J. P. Wereley Transferrin Receptor-Dependent and -Independent Iron Transport in Gallium-Resistant Human Lymphoid Leukemic Cells Blood, June 15, 1998; 91(12): 4686 - 4693. [Abstract] [Full Text] [PDF]